Table 2.
Clinical characteristics of the study population
| Eosinophillow | Eosinophilhigh | P‐value | |
|---|---|---|---|
| Age (year) | 62 ± 6 | 62 ± 4 | 0.7 |
| Gender: Male (%) | 57 | 70 | 0.5 |
| BMI (kg/m2) | 29 (18–34) | 25 (19–32) | 0.1 |
| Current smokers (%) | 43 | 60 | 0.4 |
| Pack‐years history | 42 ± 15 | 38 ± 14 | 0.4 |
| ICS use (%) | 76 | 55 | 0.2 |
| Post bronchodilator FEV1 (L) | 1.8 ± 0.4 | 1.9 ± 0.4 | 0.45 |
| Post bronchodilator FEV1 (% predicted) | 62 ± 11 | 66 ± 11 | 0.4 |
| Post bronchodilator FVC (L) | 3.7 ± 1.2 | 3.6 ± 0.9 | 0.8 |
| Post bronchodilator FEV1/FVC ratio | 50 ± 10 | 53 ± 7 | 0.3 |
| Reversibility (mL) | 190 ± 183 | 220 ± 154 | 0.6 |
| FeNO50 (ppm) | 15 (5–30) | 21 (2–61) | 0.2 |
| Atopy (% positive) | 0 | 0 | N/A |
| Total SGRQ | 42 ± 15 | 37 ± 21 | 0.4 |
| mMRC | 1 (1–4) | 1 (0–4) | 0.1 |
| CAT | 17 (5–35) | 17 (4–32) | 0.5 |
| Exacerbation rate, 12 months prior | 0 (0–3) | 0 (0–3) | 0.7 |
| Blood eosinophils (cells μL−1) | 100 (60–140) | 410 (280–890) | < 0.001 |
| Sputum eosinophils (%) | 0.5 (0.5–2.5) | 4.5 (0.25–70) | < 0.001 |
| BAL eosinophils (%) | 0 (0–3.25) | 0.75 (0–8) | 0.02 |
Data are presented as %, mean ± standard deviation, or median (range).
BMI, body mass index; CAT, COPD Assessment Test; ICS, inhaled corticosteroids; FeNO50, fractional exhaled nitric oxide at 50 mL s−1 flow rate; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; mMRC, modified Medical Research Council; PPM, parts per million; SGRQ, St George's Respiratory Questionnaire.